Matches in SemOpenAlex for { <https://semopenalex.org/work/W2398386502> ?p ?o ?g. }
- W2398386502 abstract "Background: We previously reported that nab-paclitaxel (nP) increases the pathological complete response (pCR, ypT0 ypN0) rate when it replaces solvent-based paclitaxel (P) as part of a sequential taxane followed by epirubicin/cyclophosphamide (EC) neoadjuvant chemotherapy for patients with early breast cancer (Untch et al. SABCS 2014). Here, we report efficacy and safety of patients being treated either with 150 mg/m2 nab-paclitaxel (nP150) before an amendment or with 125 mg/m2 nab-paclitaxel (nP125) thereafter in comparison to solvent-formulated paclitaxel at 80 mg/m2 (P80). Methods: In the GeparSepto study (NCT01583426), 1207 patients were randomized to either nP150 or P80 q1w for 12 weeks followed by 4 cycles of conventionally dosed EC (E: 90mg/m2; C: 600 mg/m2) q3w. The primary objective of the study was to compare the pCR rate (pCR, ypT0 ypN0). Patients with untreated, histologically confirmed uni- or bilateral, cT2- cT4d carcinoma, and no clinically relevant cardiovascular and other co-morbidities were included. Patients with HER2+ tumors received trastuzumab (loading dose 8mg/kg; 6 mg/kg) plus pertuzumab (loading dose 840 mg; 420 mg) q3w concomitantly to all chemotherapy cycles. After a safety analysis showed a higher rate of dose reductions and treatment discontinuations with nP150 compared to P80, weekly dose of nP was reduced to 125 mg/m2. Results: nP was given for the majority of cycles at a dose of 150 mg/m2 to 179 patients and at a dose of 125 mg/m2 to 426 patients. Treatment characteristics were fairly balanced between these two sequential cohorts as well as compared to 601 patients receiving P80 except for HER2 status (HER2-positive: nP150 22%, nP125 37% and P80 33%) and Ki67 ( Conclusions: Risk-benefit ratio of nP125 was improved over nP150 with better drug adherence and RTDI, lower frequency of PNP but a higher pCR rate. It should therefore be considered as the preferred schedule when nP is used as neoadjuvant treatment for primary breast cancer. The trial was financially supported by Celgene and Roche. Citation Format: von Minckwitz G, Untch M, Jakisch C, Schneeweiss A, Conrad B, Aktas B, Denkert C, Eidtmann H, Weibringhaus H, Kummel S, Hilfrich J, Warm M, Paepke S, Just M, Hanusch C, Hackmann J, Blohmer J-U, Clemens M, Costa SD, Gerber B, Nekljudova V, Loibl S. nab-paclitaxel at a dose of 125 mg/m2 weekly is more efficacious but less toxic than at 150 mg/m2. Results from the neoadjuvant randomized GeparSepto study (GBG 69). [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr P1-14-11." @default.
- W2398386502 created "2016-06-24" @default.
- W2398386502 creator A5002071285 @default.
- W2398386502 creator A5004942036 @default.
- W2398386502 creator A5006857767 @default.
- W2398386502 creator A5007224833 @default.
- W2398386502 creator A5010482169 @default.
- W2398386502 creator A5014738808 @default.
- W2398386502 creator A5014883814 @default.
- W2398386502 creator A5027184783 @default.
- W2398386502 creator A5033698551 @default.
- W2398386502 creator A5045473868 @default.
- W2398386502 creator A5056873538 @default.
- W2398386502 creator A5057181684 @default.
- W2398386502 creator A5058648380 @default.
- W2398386502 creator A5060674793 @default.
- W2398386502 creator A5069170386 @default.
- W2398386502 creator A5071658752 @default.
- W2398386502 creator A5080084748 @default.
- W2398386502 creator A5081701145 @default.
- W2398386502 creator A5087224341 @default.
- W2398386502 creator A5087559224 @default.
- W2398386502 creator A5088568624 @default.
- W2398386502 creator A5089392438 @default.
- W2398386502 date "2016-02-15" @default.
- W2398386502 modified "2023-09-27" @default.
- W2398386502 title "Abstract P1-14-11: nab-paclitaxel at a dose of 125 mg/m2weekly is more efficacious but less toxic than at 150 mg/m2. Results from the neoadjuvant randomized GeparSepto study (GBG 69)" @default.
- W2398386502 doi "https://doi.org/10.1158/1538-7445.sabcs15-p1-14-11" @default.
- W2398386502 hasPublicationYear "2016" @default.
- W2398386502 type Work @default.
- W2398386502 sameAs 2398386502 @default.
- W2398386502 citedByCount "1" @default.
- W2398386502 countsByYear W23983865022016 @default.
- W2398386502 crossrefType "proceedings-article" @default.
- W2398386502 hasAuthorship W2398386502A5002071285 @default.
- W2398386502 hasAuthorship W2398386502A5004942036 @default.
- W2398386502 hasAuthorship W2398386502A5006857767 @default.
- W2398386502 hasAuthorship W2398386502A5007224833 @default.
- W2398386502 hasAuthorship W2398386502A5010482169 @default.
- W2398386502 hasAuthorship W2398386502A5014738808 @default.
- W2398386502 hasAuthorship W2398386502A5014883814 @default.
- W2398386502 hasAuthorship W2398386502A5027184783 @default.
- W2398386502 hasAuthorship W2398386502A5033698551 @default.
- W2398386502 hasAuthorship W2398386502A5045473868 @default.
- W2398386502 hasAuthorship W2398386502A5056873538 @default.
- W2398386502 hasAuthorship W2398386502A5057181684 @default.
- W2398386502 hasAuthorship W2398386502A5058648380 @default.
- W2398386502 hasAuthorship W2398386502A5060674793 @default.
- W2398386502 hasAuthorship W2398386502A5069170386 @default.
- W2398386502 hasAuthorship W2398386502A5071658752 @default.
- W2398386502 hasAuthorship W2398386502A5080084748 @default.
- W2398386502 hasAuthorship W2398386502A5081701145 @default.
- W2398386502 hasAuthorship W2398386502A5087224341 @default.
- W2398386502 hasAuthorship W2398386502A5087559224 @default.
- W2398386502 hasAuthorship W2398386502A5088568624 @default.
- W2398386502 hasAuthorship W2398386502A5089392438 @default.
- W2398386502 hasConcept C121608353 @default.
- W2398386502 hasConcept C126322002 @default.
- W2398386502 hasConcept C126894567 @default.
- W2398386502 hasConcept C141071460 @default.
- W2398386502 hasConcept C2776694085 @default.
- W2398386502 hasConcept C2776755627 @default.
- W2398386502 hasConcept C2777292972 @default.
- W2398386502 hasConcept C2777511904 @default.
- W2398386502 hasConcept C2778300832 @default.
- W2398386502 hasConcept C2779786085 @default.
- W2398386502 hasConcept C2780835546 @default.
- W2398386502 hasConcept C2781164504 @default.
- W2398386502 hasConcept C530470458 @default.
- W2398386502 hasConcept C71924100 @default.
- W2398386502 hasConcept C90924648 @default.
- W2398386502 hasConceptScore W2398386502C121608353 @default.
- W2398386502 hasConceptScore W2398386502C126322002 @default.
- W2398386502 hasConceptScore W2398386502C126894567 @default.
- W2398386502 hasConceptScore W2398386502C141071460 @default.
- W2398386502 hasConceptScore W2398386502C2776694085 @default.
- W2398386502 hasConceptScore W2398386502C2776755627 @default.
- W2398386502 hasConceptScore W2398386502C2777292972 @default.
- W2398386502 hasConceptScore W2398386502C2777511904 @default.
- W2398386502 hasConceptScore W2398386502C2778300832 @default.
- W2398386502 hasConceptScore W2398386502C2779786085 @default.
- W2398386502 hasConceptScore W2398386502C2780835546 @default.
- W2398386502 hasConceptScore W2398386502C2781164504 @default.
- W2398386502 hasConceptScore W2398386502C530470458 @default.
- W2398386502 hasConceptScore W2398386502C71924100 @default.
- W2398386502 hasConceptScore W2398386502C90924648 @default.
- W2398386502 hasLocation W23983865021 @default.
- W2398386502 hasOpenAccess W2398386502 @default.
- W2398386502 hasPrimaryLocation W23983865021 @default.
- W2398386502 hasRelatedWork W1569344663 @default.
- W2398386502 hasRelatedWork W2091814351 @default.
- W2398386502 hasRelatedWork W2184113500 @default.
- W2398386502 hasRelatedWork W2206771146 @default.
- W2398386502 hasRelatedWork W2242778622 @default.
- W2398386502 hasRelatedWork W2246876973 @default.
- W2398386502 hasRelatedWork W2332421562 @default.
- W2398386502 hasRelatedWork W2342658692 @default.
- W2398386502 hasRelatedWork W2587356754 @default.
- W2398386502 hasRelatedWork W2590638453 @default.
- W2398386502 hasRelatedWork W2594784959 @default.